This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-shhttp://sh.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n4https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbpedia-ruhttp://ru.dbpedia.org/resource/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n22http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
dbpedia-srhttp://sr.dbpedia.org/resource/
freebasehttp://rdf.freebase.com/ns/
n6http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
dbpedia-ithttp://it.dbpedia.org/resource/
dbpedia-zhhttp://zh.dbpedia.org/resource/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:NSI-189
rdf:type
yago:PhysicalEntity100001930 yago:LivingThing100004258 yago:Whole100003553 yago:Drug103247620 yago:Matter100020827 yago:StemCell105607863 yago:Agent114778436 yago:PsychoactiveDrug104017137 yago:WikicatStemCells dbo:Drug wikidata:Q8386 owl:Thing yago:Object100002684 n22:ChemicalObject dbo:ChemicalSubstance yago:Cell100006484 yago:Substance100020090 yago:CausalAgent100007347 yago:SomaticCell105430628 yago:WikicatPsychoactiveDrugs
rdfs:label
NSI-189 NSI-189 NSI-189 NSI-189
rdfs:comment
NSI-189 è un composto ad attività neurotrofica in studio, da parte della società americana Neuralstem, per il trattamento di diversi disturbi psichiatrici e neurologici come la depressione o malattie neurodegenerative. NSI-189 is an experimental, potential antidepressant that was developed by Neuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration. A phase II clinical trial for MDD failed to meet the primary depression endpoint (MADRS) in July 2017, although statistically significant improvements have been reported on a number of secondary depression and cognition endpoints. In 2021, Neuralstem merged with another company to become Palisade Bio, who in 2021 sold NSI-189 to an unknown buyer for up to $4.9 million. NSI-189 — экспериментальный препарат, проявляющий антидепрессивную и ноотропную активность. Корпорация Neuralstem производит клинические испытания эффективности препарата при большом депрессивном расстройстве и планирует проводить его клинические испытания для ряда других неврологических состояний. NSI-189是一個,由開發的抗抑鬱藥。用於治療重性抑郁障碍 (MDD), 認知障礙以及神经退行性疾病. 相關研究由美國國防高等研究計劃署 (DARPA)以及國立衛生研究院 (NIH)出資。 NSI-189的作用機轉為在海馬迴增強的神經元新生以及其體積的增大，但NSI-189達成此效果的機轉尚不明朗。目前為止無法找出其。 此藥物由對10,269種化合物進行而發現，其過程為尋找in vitro環境下有神經新生特性的化合物。
foaf:depiction
n6:NSI-189_structure.svg
dcterms:subject
dbc:Antidepressants dbc:Nicotinamides dbc:Drugs_with_unknown_mechanisms_of_action dbc:Nootropics dbc:Piperazines dbc:Aminopyridines
dbo:wikiPageID
40541446
dbo:wikiPageRevisionID
1063089522
dbo:wikiPageWikiLink
dbr:Effect_size dbc:Antidepressants dbc:Nicotinamides dbr:Major_depressive_disorder dbr:Post-traumatic_stress_disorder dbr:Oral_administration dbr:Cognitive_impairment dbc:Drugs_with_unknown_mechanisms_of_action dbr:Neurogenesis dbc:Nootropics dbr:Clinical_trial dbr:Memory_and_aging dbr:Neurodegeneration dbr:Experimental_drug dbr:Alzheimer's_disease dbr:Antidepressant dbr:Neuralstem,_Inc. dbr:Traumatic_brain_injury dbr:Drug_target dbr:Stroke dbr:Neurological_condition dbc:Piperazines dbr:Chemical_library dbr:Phases_of_clinical_research dbr:List_of_investigational_antidepressants dbr:Cohen_s_d dbc:Aminopyridines dbr:Phenotypic_screening
owl:sameAs
n4:YXS7 dbpedia-ru:NSI-189 freebase:m.0x215j8 dbpedia-sh:NSI-189 dbpedia-sr:NSI-189 yago-res:NSI-189 wikidata:Q15409359 dbpedia-it:NSI-189 dbpedia-zh:NSI-189
dbp:wikiPageUsesTemplate
dbt:Drugbox dbt:Stdinchicite dbt:Antidepressants dbt:Reflist dbt:Abbrlink dbt:Cite_journal
dbo:thumbnail
n6:NSI-189_structure.svg?width=300
dbp:c
22
dbp:casNumber
1270138
dbp:chemspiderid
32701740
dbp:eliminationHalfLife
17.4
dbp:h
30
dbp:iupacName
-[2-pyridin-3-yl]methanone
dbp:legalUs
Investigational New Drug
dbp:n
4
dbp:o
1
dbp:pregnancyUs
N
dbp:pubchem
50922681
dbp:routesOfAdministration
dbr:Oral_administration
dbp:smiles
CCCCNC1=CCN2CCNCC3=CC=CC=C3
dbp:stdinchi
1
dbp:stdinchikey
DYTOQURYRYYNOR-UHFFFAOYSA-N
dbp:unii
YVE9U408ZL
dbp:width
250
dbo:abstract
NSI-189 — экспериментальный препарат, проявляющий антидепрессивную и ноотропную активность. Корпорация Neuralstem производит клинические испытания эффективности препарата при большом депрессивном расстройстве и планирует проводить его клинические испытания для ряда других неврологических состояний. NSI-189 è un composto ad attività neurotrofica in studio, da parte della società americana Neuralstem, per il trattamento di diversi disturbi psichiatrici e neurologici come la depressione o malattie neurodegenerative. NSI-189 is an experimental, potential antidepressant that was developed by Neuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration. A phase II clinical trial for MDD failed to meet the primary depression endpoint (MADRS) in July 2017, although statistically significant improvements have been reported on a number of secondary depression and cognition endpoints. The compound's activity was discovered using phenotypic screening with a library of 10,269 compounds to identify compounds that promoted neurogenesis in vitro. As of 2016 the target of the compound was unknown but it appeared to promote neurogenesis in rodents. NSI-189 completed a phase I clinical trial for MDD in 2011, where it was administered to 41 healthy volunteers. A phase Ib clinical trial for treating MDD in 24 patients started in 2012 and completed in July 2014, with results published in December 2015. In July 2017, it was announced that a phase II clinical trial with 220 patients failed to meet its primary effectiveness endpoint in MDD. Upon the announcement, Neuralstem stock plummeted by 61%. More detailed analysis of the trial results was released in December 2017 and January 2018. It revealed statistically significant improvements on patient-reported depression scales and in aspects of cognition for the 40 mg/day dose. Of particular note are improvements in memory (effect size Cohen's d = 1.12, p = 0.002), working memory (d = 0.81, p = 0.020), and executive functioning (d = 0.66, p = 0.048) as measured by the CogScreen computerized test. In August 2020 another phase 2 study with 220 participants was done. A 80 mg dose of NSI-189 showed significant benefit over placebo in the subgroup of patients who were moderately depressed (MADRS < 30) but was not significant in patients who were severely depressed (MADRS ≥ 30). The study concludes that NSI-189 is effective as a safe adjunctive therapy, with most compelling antidepressant and procognitive benefits noted in patients with moderate depression. In addition to MDD, Neuralstem has said that it intends to pursue clinical development of NSI-189 for a variety of other neurological conditions, including traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and to prevent cognitive and memory decline in aging. In 2021, Neuralstem merged with another company to become Palisade Bio, who in 2021 sold NSI-189 to an unknown buyer for up to $4.9 million. NSI-189是一個,由開發的抗抑鬱藥。用於治療重性抑郁障碍 (MDD), 認知障礙以及神经退行性疾病. 相關研究由美國國防高等研究計劃署 (DARPA)以及國立衛生研究院 (NIH)出資。 NSI-189的作用機轉為在海馬迴增強的神經元新生以及其體積的增大，但NSI-189達成此效果的機轉尚不明朗。目前為止無法找出其。 此藥物由對10,269種化合物進行而發現，其過程為尋找in vitro環境下有神經新生特性的化合物。
gold:hypernym
dbr:Drug
prov:wasDerivedFrom
wikipedia-en:NSI-189?oldid=1063089522&ns=0
dbo:wikiPageLength
8882
dbo:casNumber
1270138-40-3
dbo:fdaUniiCode
YVE9U408ZL
dbo:pubchem
50922681
foaf:isPrimaryTopicOf
wikipedia-en:NSI-189